HeartFlow Analysis vs AI-CVD
AI Verdict
Choose HeartFlow Analysis if…
Choose HeartFlow Analysis if you need a precise, non-invasive diagnostic assessment of coronary artery disease (CAD) in patients with suspected or known CAD, particularly when evaluating the functional significance of stenoses. This tool excels at providing detailed 3D models, FFRct analysis, and plaque characterization to inform treatment decisions without invasive procedures.
View HeartFlow Analysis →Choose AI-CVD if…
Choose AI-CVD if your goal is opportunistic screening for a broad range of cardiovascular and multisystem diseases using existing CT scans, without requiring additional imaging or workflow changes. This platform is ideal for proactively identifying hidden health risks through automated measurements like Coronary Artery Calcium (CAC) scoring and cardiac chamber volumetry from scans already performed for other indications.
View AI-CVD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | HeartFlow Analysis | AI-CVD |
|---|---|---|
| Pricing | Contact vendor for pricing | Unknown |
| Deployment | Cloud-based (AWS) | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AI-CVDTool B (AI-CVD) explicitly highlights 'no additional imaging, radiation, contrast, or workflow disruption' by utilizing existing CT scans for opportunistic screening. This suggests a highly seamless integration into current clinical workflows with minimal overhead. While Tool A (HeartFlow Analysis) also uses standard CT scans, its output involves detailed 3D models and FFRct analysis, which may require specialized interpretation and workflow adjustments.
Clinical Value
HeartFlow AnalysisTool A (HeartFlow Analysis) offers deep, specific diagnostic value for coronary artery disease (CAD) through FFRct analysis and plaque characterization, which are crucial for guiding intervention and treatment decisions. While Tool B (AI-CVD) provides broad opportunistic screening for various cardiovascular risk factors, Tool A's functional assessment of CAD is a more direct and established diagnostic tool with high diagnostic accuracy for managing CAD.
Pricing & Value
HeartFlow AnalysisTool A (HeartFlow Analysis) has a significant advantage with established Category I CPT codes for FFRct Analysis and AI-Enabled Quantitative Plaque Analysis, and its services are covered by Medicare and most U.S. commercial payers. This provides clear reimbursement pathways and financial predictability for healthcare providers. Tool B (AI-CVD) only states 'contact for pricing' with no mention of specific CPT codes or reimbursement, which can be a barrier to adoption.
Enterprise Readiness
HeartFlow AnalysisBoth tools are cloud-based and FDA-cleared. However, Tool A (HeartFlow Analysis) explicitly states 'has_baa': 'yes' and 'hipaa_compliant': 'yes' in its specifications. Tool B (AI-CVD) uses 'likely, contact vendor' for these crucial enterprise readiness aspects, making Tool A's compliance and readiness more clearly confirmed in the provided data.
Innovation
HeartFlow AnalysisBoth tools leverage AI for advanced analysis. HeartFlow Analysis's FFRct, which uses AI and computational fluid dynamics to derive functional blood flow information from standard CT scans, was a groundbreaking innovation that significantly impacted non-invasive CAD assessment. While AI-CVD's broad opportunistic screening is innovative in its scope, FFRct fundamentally changed the diagnostic pathway for CAD.
Support & Docs
TieNeither the provided structured facts nor web searches offered specific comparative details regarding the depth or accessibility of support and documentation for either tool. Both are commercial-stage medical technology companies, implying they offer necessary support, but without explicit information to differentiate, it's a tie. HeartFlow's website mentions comprehensive support including training, technology integration, and coding/reimbursement assistance.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | HeartFlow Analysis | AI-CVD |
|---|---|---|
| Name | HeartFlow Analysis | AI-CVD |
| Company | HeartFlow | HeartLung Corporation |
| Description | Commercial-stage medical technology company providing software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans. | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. |
| Key Features | AI-powered 3D modeling of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, Plaque Analysis (quantification and characterization), Roadmapu2122 Analysis for CCTA reading, Non-invasive diagnostic assessment, Personalized patient insights, Computational Fluid Dynamics (CFD) for blood flow simulation, High diagnostic accuracy | Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, No additional imaging, radiation, contrast, or workflow disruption, Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring HeartFlow Analysis and AI-CVD.